Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006-2021

MLA

Ludwig Dubois, et al. “Hypoxia-Activated Prodrug Derivatives of Anti-Cancer Drugs: A Patent Review 2006-2021.” Expert Opinion on Therapeutic Patents, vol. 32, no. 1, Jan. 2022, pp. 1–12. EBSCOhost, https://doi.org/10.1080/13543776.2021.1954617.

APA

Ludwig Dubois, Jean-Yves Winum, Emilie Anduran, & Philippe Lambin. (2022). Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006-2021. Expert Opinion on Therapeutic Patents, 32(1), 1–12. https://doi.org/10.1080/13543776.2021.1954617

Chicago

Ludwig Dubois, Jean-Yves Winum, Emilie Anduran, and Philippe Lambin. 2022. “Hypoxia-Activated Prodrug Derivatives of Anti-Cancer Drugs: A Patent Review 2006-2021.” Expert Opinion on Therapeutic Patents 32 (1): 1–12. doi:10.1080/13543776.2021.1954617.